Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial

Nobile‐Orazio, Eduardo; Cocito, Dario; Jann, Stefano; Uncini, Antonino; Beghi, Ettore; Messina, Paolo; Antonini, Giovanni; Fazio, Raffaella; Gallia, Francesca; Schenone, Angelo; Francia, Ada; Pareyson, Davide; Santoro, Lucio; Tamburin, Stefano; Macchia, Roberta; Cavaletti, Guido; Giannini, F.; Sabatelli, Mario

doi:10.1016/s1474-4422(12)70093-5

Cited by 191 publications

(162 citation statements)

References 34 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…A comparative study has been published [55], which assessed efficacy and tolerability of IVIG (0.5 g/kg/day for 4 consecutive days) and high-dose intravenous methylprednisolone (IVMP) (0.5 g/day for 4 consecutive days) given every month for 6 consecutive months. This double-blinded RCT was completed in 45 patients (24 IVIG, 21 IVMP).…”

Section: Comparative Trialsmentioning

confidence: 99%

Immunotherapy in Peripheral Neuropathies

Léger¹,

Guimarães‐Costa²,

Muntean³

2016

Neurotherapeutics

View full text Add to dashboard Cite

Immunotherapy has been investigated in a small subset of peripheral neuropathies, including an acute one, Guillain-Barré syndrome, and 3 chronic forms: chronic inflammatory demyelinating polyradiculoneuropathy, multifocal motor neuropathy, and neuropathy associated with IgM anti-myelin-associated glycoprotein. Several experimental studies and clinical data are strongly suggestive of an immune-mediated pathogenesis. Either cell-mediated mechanisms or antibody responses to Schwann cell, compact myelin, or nodal antigens are considered to act together in an aberrant immune response to cause damage to peripheral nerves. Immunomodulatory treatments used in these neuropathies aim to act at various steps of this pathogenic process. However, there are many phenotypic variants and, consequently, there is a significant difference in the response to immunotherapy between these neuropathies, as well as a need to improve our knowledge and long-term management of chronic forms.

show abstract

Section: Comparative Trialsmentioning

confidence: 99%

Immunotherapy in Peripheral Neuropathies

Léger¹,

Guimarães‐Costa²,

Muntean³

2016

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…The short-term efficacy of intravenous immunoglobulin is similar to that of plasma exchange and corticosteroid therapy but with a better tolerance profile. 12 The benefit of immunoglobulin is transient, however, and long-term management of the disease may require regular infusions.…”

Section: Neurologic Disordersmentioning

confidence: 99%

Intravenous immunoglobulin as clinical immune-modulating therapy

Gilardin

Bayry

Kaveri

2015

CMAJ

View full text Add to dashboard Cite

“…Another recent, multi-centre, randomized, double-blind, placebo controlled, parallel-group study in 45 patients with CIDP compared the efficacy and tolerability of IVIG (0·5 g/kg/day for 4 consecutive days) to intravenous methylprednisolone (0·5 g/day for 4 consecutive days) given every month for 6 months [37]. After therapy discontinuation, patients were followed-up for 6 months to assess relapses.…”

Section: Immunomodulation With Intravenous Immunoglobulins (Ivig)mentioning

confidence: 99%

Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies

Melzer

Meuth

2014

Clin Exp Immunol

View full text Add to dashboard Cite

OTHER ARTICLES PUBLISHED IN THIS SERIESParaneoplastic neurological syndromes. Clinical and Experimental Immunology 2014, 175: 336-48. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clinical and Experimental Immunology 2014, 175: 349-58. Monoclonal antibodies in treatment of multiple sclerosis. Clinical and Experimental Immunology 2014, 175: 373-84 SummaryMultiple sclerosis (MS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) represent chronic, autoimmune demyelinating disorders of the central and peripheral nervous system. Although both disorders share some fundamental pathogenic elements, treatments do not provide uniform effects across both disorders. We aim at providing an overview of current and future disease-modifying strategies in these disorders to demonstrate communalities and distinctions.

show abstract

Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial

Cited by 191 publications

References 34 publications

Immunotherapy in Peripheral Neuropathies

Immunotherapy in Peripheral Neuropathies

Intravenous immunoglobulin as clinical immune-modulating therapy

Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies

Contact Info

Product

Resources

About